Mastering Schizophrenia Treatment: Optimal Use of Oral Antipsychotics Based on Neurobiological and Clinical Evidence

FACULTY

Leslie L. Citrome, MD, MPH
Clinical Professor
Department of Psychiatry & Behavioral Sciences
New York Medical College
Valhalla, New York

Christoph U. Correll, MD
Professor of Psychiatry, Chair Child and Adolescent Psychiatry
(1) Donald and Barbara Zucker School of Medicine at Hofstra/Northwell;
(2) The Zucker Hillside Hospital;
(3) The Feinstein Institutes for Medical Research;
(4) Charité - Universitätsmedizin Berlin
New York, New York

Erin Crown, MHS, PA-C, CAQ-Psychiatry
Managing Member, Oasis LifeCare, LLC
Owner, Future Options Research, LLC
State College, Pennsylvania

PROVIDER STATEMENT

Provided by HMP Education, an HMP Global Company.

INTENDED LEARNERS

This educational activity is specifically designed for psychiatrists, psychiatric/mental health nurse practitioners (NPs), advanced practice nurses (APRNs), physician associates/assistants (PAs), primary care practitioners (PCPs), nurses, and the full multidisciplinary team of behavioral and mental health professionals who seek to improve the care of patients with mental health disorders.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

• Assess the burdens of schizophrenia and common challenges and shortcomings in its treatment  
• Describe the evolution of neurobiological models of schizophrenia, focusing on the role of presynaptic mechanisms and multiple neurotransmitters in addition to dopamine 
• Summarize the current utilization of OAPs for schizophrenia that target postsynaptic D2 receptors and the potential benefits and risks associated with this traditional approach 
• Evaluate the latest clinical evidence and treatment implications associated with newer OAPs for schizophrenia that have presynaptic and multimodal mechanisms of action 
• Identify strategies to individualize OAP treatments for patients with schizophrenia, optimizing efficacy and safety with careful consideration of comorbidities and drug-drug interactions 
• Apply shared decision-making techniques to improve OAP adherence, monitoring, and overall treatment outcomes in patients with schizophrenia 

ACTIVITY OVERVIEW

To be eligible for documentation of credit for each session attended, learners must participate in the activity and complete the session(s) and overall conference evaluations. Participants who complete the evaluation online within 30 days of the conference will receive documentation of credit. Your certificate may not load if you are accessing it from a smartphone, or settings of your browser do not allow for a new tab/window to open.  

Once a certificate has been claimed, physicians and pharmacists may elect for credits to be submitted on their behalf to their boards via additional fields that will appear within the Claim Certificate page. Credits must be submitted through this process to be reported to the American Board of Surgery and the National Association of Boards of Pharmacy. 

Live Date: December 18, 2025 
Estimated Time to Complete: 2 hours

There is no fee associated with this activity.

HARDWARE/SOFTWARE REQUIREMENTS

The activity is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. 

CONTINUING EDUCATION

In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.

PHYSICIANS

HMP Education designates this internet live activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS

This internet live, knowledge-based activity (Universal Activity Number: JA0006201-0000-25-538-L01-P) has been approved for a maximum of 2.00 contact hours (0.2 CEUs).

Note: The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, credit must be transmitted to NABP through CPE Monitor within 60 days from the date you complete this CPE activity.  

NURSES

This continuing nursing education internet live activity awards 2.00 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #18006 for 2.00 contact hours. 

NURSE PRACTITIONERS

American of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit^TM from organizations accredited by the ACCME.

PHYSICIAN ASSOCIATES/ASSISTANTS

HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet live activity is designated for 2.00 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

INTERNATIONAL RECOGNITION

Visit this link for countries and regions have reciprocity with the ACCME.  

Visit this link for additional countries that accept ACCME-accredited continuing medical education (CME). 

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters, or moderators and do not necessarily reflect the opinions of HMP Education.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own healthcare provider.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority. 

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to and mitigating all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME. 

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose: 

1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and; 

2. Any investigational, off-label, or non-FDA approved content or discussion 

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner. 

Education has been independently peer-reviewed to validate content, mitigate identified financial relationships (conflicts of interest), and ensure: 

1. All recommendations involving clinical medicine are based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients. 

2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis. 

3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional. 

All relevant financial relationships have been mitigated. 

FACULTY

The faculty have reported the following: 

Leslie L. Citrome, MD, MPH: Consultant—AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Bristol-Myers Squibb, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda, Wells Fargo, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; Royalties/Publishing Income—Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022-date), Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics); Speakers Bureau—AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Bristol-Myers Squibb, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, Vanda, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies; Stocks—(small number of shares of common stock): Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased > 10 years ago, stock options: Reviva 

Christoph Correll, MD: Advisory Board - AbbVie, Alkermes, Allergan, Angelini, BMS, Boehringer Ingelheim, Bristol-Meyers Squibb, Cerevel, Compass, Gedeon Richter, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Merck, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Rovi, Sage, Seqirus, Life Science, Sunovion, Supernus, Teva, Vertex, Viatris; Consultant - AbbVie, Alkermes, Allergan, Angelini, Autobahn, Boehringer Ingelheim, Bristol-Meyers Squibb, Cerevel, Compass, Denovo, Eli Lilly, Gedeon Richter, GH, IntraCellular Therapies, Janssen/J&J, Karuna, Kuleon Biosciences, LB Pharma, Lundbeck, MedInCell, Medlink, Merck, Mindpax, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, Life Science, Sunovion, Supernus, Teva, Vertex, Viatris; Grant/Research Support - Boehringer-Ingelheim, Janssen, Takeda

Erin Crown,MHS, PA-C, CAQ-Psychiatry: Consultant - Abbvie, Axsome, Bristol Myers Squibb, Intracellular, Janssen, Lunbeck, Neurocrine, Otsuka, Supernus; Speaker's Bureau - Axsome, Bristol Myers Squibb, Janssen, Intracellular, Lunbeck, Neurocrine, Otsuka, Supernus

CLINICAL REVIEWER

Craig Chepke, MD, DFAPA
Adjunct Associate Professor of Psychiatry, Atrium Health
Medical Director, Excel Psychiatric Associates
Huntersville, North Carolina 

Craig Chepke, MD, DFAPA: Advisory Board—AbbVie, Acadia, Alkermes, Axsome, Biogen, Bristol Myers Squibb, Corium, Idorsia, Intracellular, Johnson & Johnson, Lundbeck, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Teva; Advisory Board (Spouse)—Otsuka; Consultant—AbbVie, Acadia, Alkermes, Axsome, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intracellular, Johnson & Johnson, Lundbeck, MedinCell, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Supernus, Teva; Grant Research/Support—Acadia, Axsome, Harmony, Neurocrine, Teva; Speakers Bureau—AbbVie, Acadia, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intracellular, Johnson & Johnson, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sumitomo, Teva

PLANNING COMMITTEE

Planning for this activity was conducted by faculty advisors. To further support the development of the content, additional information regarding professional roles, responsibilities, and teamwork was gathered through survey input from our target audience and/or a comprehensive literature review.  

HMP Education planners and staff include Jillian Battista; Meaghan Benci; Brielle Calleo; Kristin Ciszeski; Meghan Flanagan; Samantha Joy; Randy Robbin; and Andrea Zimmerman, EdD, CHCP. No HMP Education staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

ADA STATEMENT

HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. Any participant in this educational activity who needs accommodation(s) may submit a request to the support team. 

PRIVACY POLICY

HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information. 

COMMERCIAL SUPPORT

Supported by an educational grant from Johnson & Johnson.

CONTACT US 

For immediate assistance, please explore our HMP Education Help Center or chat with our Virtual CE Assistant, which can answer most common questions related to claiming credits and the HMP Education website. If you have a question or grievance that cannot be answered by our Virtual CE assistant and Help Center, please submit a request to contact the support team. Our accreditation and compliance team will respond to your inquiry within one business day. 

 

Copyright © 2025 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.